FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201880991> ?p ?o ?g. }

• W3201880991 abstract "Abstract Background Rheumatoid arthritis is a progressive and systemic autoimmune disease seriously compromises human health. Fibroblast like synoviocytes are the major effectors of proliferation and inflammation in rheumatoid arthritis synovial tissue. Shikonin has anti-inflammatory and immunomodulatory activities. But, its role on synovitis of rheumatoid arthritis is unknown. Methods The DBA/1 male mice were randomly divided into the following three groups (n = 6): (1) the normal control group of mice, (2) the CIA (collagen-induced arthritis) group in which mice suffered from arthritis induced by collagen, (3) the SKN (shikonin) group of mice which got arthritis and given intragastrically with shikonin 4 mg/kg per day continuously for 20 days,(4) the MTX (methotrexate) group of mice which got arthritis and orally administration with shikonin 0.5 mg/kg once two days continuously for 20 days. The therapeutic effect of shikonin on collagen induced arthritis mice was tested by arthritis incidence rate, arthritis score and inflammatory joint histopathology. The invasion, adhesion and migration of fibroblast like synoviocytes induced by tumor necrosis factor-α were applied to measure the anti-synovitis role of shikonin. The effect of shikonin on expression of interleukin-6, interleukin-1β and tumor necrosis factor-α was measured by enzyme linked immunosorbent assay. The interaction between shikonin and suppressor of cytokine signaling 1 was verified by molecular docking. The signaling pathways activated by shikonin were measured by western blot. Results Shikonin decreased the arthritis score and arthritis incidence, and inhibited inflammation of inflamed joints in collagen induced arthritis mice. And shikonin reduced the number of vimentin + cells in collagen induced arthritis mice inflamed joints. Meanwhile, shikonin suppressed tumor necrosis factor-α-induced invasion, adhesion and migration of fibroblast like synoviocytes and reduced the expression of interleukin-6, interleukin-1β and tumor necrosis factor-α. And we found that shikonin targeted suppressor of cytokine signaling 1. More interestingly, shikonin blocked the phosphorylation of Janus kinase 1/signal transducer andactivator of transcription 1/signal transducer andactivator of transcription 6 in synovial tissues and in fibroblast like synoviocytes. Conclusion Shikonin represents a promising new anti-rheumatoid arthritis drug candidate that has anti-synovitis effect in collagen induced arthritis mice and inhibits tumor necrosis factor-α-induced fibroblast like synoviocytes by targeting suppressor of cytokine signaling 1/ Janus kinase/signal transducer andactivator of transcription signaling pathway. These findings demonstrate that shikonin has anti-synovitis effect and has great potential to be a new drug for the treatment of rheumatoid arthritis." @default.
• W3201880991 created "2021-10-11" @default.
• W3201880991 creator A5006538333 @default.
• W3201880991 creator A5015090467 @default.
• W3201880991 creator A5024917626 @default.
• W3201880991 creator A5061373308 @default.
• W3201880991 creator A5064827774 @default.
• W3201880991 creator A5065619668 @default.
• W3201880991 creator A5072312460 @default.
• W3201880991 creator A5080451362 @default.
• W3201880991 creator A5082022764 @default.
• W3201880991 creator A5082335856 @default.
• W3201880991 date "2021-10-02" @default.
• W3201880991 modified "2023-10-14" @default.
• W3201880991 title "Shikonin attenuates rheumatoid arthritis by targeting SOCS1/JAK/STAT signaling pathway of fibroblast like synoviocytes" @default.
• W3201880991 cites W1516679274 @default.
• W3201880991 cites W1530717069 @default.
• W3201880991 cites W1557244763 @default.
• W3201880991 cites W1583798678 @default.
• W3201880991 cites W1873126901 @default.
• W3201880991 cites W1885001816 @default.
• W3201880991 cites W1968042102 @default.
• W3201880991 cites W1986569175 @default.
• W3201880991 cites W1993026462 @default.
• W3201880991 cites W2025851689 @default.
• W3201880991 cites W2033912854 @default.
• W3201880991 cites W2036422868 @default.
• W3201880991 cites W2046830010 @default.
• W3201880991 cites W2059820407 @default.
• W3201880991 cites W2060808005 @default.
• W3201880991 cites W2061687700 @default.
• W3201880991 cites W2076357723 @default.
• W3201880991 cites W2084635480 @default.
• W3201880991 cites W2093442991 @default.
• W3201880991 cites W2110826367 @default.
• W3201880991 cites W2117382612 @default.
• W3201880991 cites W2124162601 @default.
• W3201880991 cites W2138119947 @default.
• W3201880991 cites W2142152378 @default.
• W3201880991 cites W2152348310 @default.
• W3201880991 cites W2155872278 @default.
• W3201880991 cites W2160578379 @default.
• W3201880991 cites W2181309336 @default.
• W3201880991 cites W2189352316 @default.
• W3201880991 cites W2559901169 @default.
• W3201880991 cites W2801619949 @default.
• W3201880991 cites W2803973097 @default.
• W3201880991 cites W2804822363 @default.
• W3201880991 cites W2892635078 @default.
• W3201880991 cites W2903845458 @default.
• W3201880991 cites W2921533346 @default.
• W3201880991 cites W2955622142 @default.
• W3201880991 cites W3006929163 @default.
• W3201880991 cites W3029836818 @default.
• W3201880991 cites W3041249443 @default.
• W3201880991 cites W3103651641 @default.
• W3201880991 doi "https://doi.org/10.1186/s13020-021-00510-6" @default.
• W3201880991 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8487562" @default.
• W3201880991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34600581" @default.
• W3201880991 hasPublicationYear "2021" @default.
• W3201880991 type Work @default.
• W3201880991 sameAs 3201880991 @default.
• W3201880991 citedByCount "7" @default.
• W3201880991 countsByYear W32018809912022 @default.
• W3201880991 countsByYear W32018809912023 @default.
• W3201880991 crossrefType "journal-article" @default.
• W3201880991 hasAuthorship W3201880991A5006538333 @default.
• W3201880991 hasAuthorship W3201880991A5015090467 @default.
• W3201880991 hasAuthorship W3201880991A5024917626 @default.
• W3201880991 hasAuthorship W3201880991A5061373308 @default.
• W3201880991 hasAuthorship W3201880991A5064827774 @default.
• W3201880991 hasAuthorship W3201880991A5065619668 @default.
• W3201880991 hasAuthorship W3201880991A5072312460 @default.
• W3201880991 hasAuthorship W3201880991A5080451362 @default.
• W3201880991 hasAuthorship W3201880991A5082022764 @default.
• W3201880991 hasAuthorship W3201880991A5082335856 @default.
• W3201880991 hasBestOaLocation W32018809911 @default.
• W3201880991 hasConcept C126322002 @default.
• W3201880991 hasConcept C17991360 @default.
• W3201880991 hasConcept C203014093 @default.
• W3201880991 hasConcept C2776914184 @default.
• W3201880991 hasConcept C2777077863 @default.
• W3201880991 hasConcept C2777575956 @default.
• W3201880991 hasConcept C2777652487 @default.
• W3201880991 hasConcept C2778690821 @default.
• W3201880991 hasConcept C2779244835 @default.
• W3201880991 hasConcept C71924100 @default.
• W3201880991 hasConcept C98274493 @default.
• W3201880991 hasConceptScore W3201880991C126322002 @default.
• W3201880991 hasConceptScore W3201880991C17991360 @default.
• W3201880991 hasConceptScore W3201880991C203014093 @default.
• W3201880991 hasConceptScore W3201880991C2776914184 @default.
• W3201880991 hasConceptScore W3201880991C2777077863 @default.
• W3201880991 hasConceptScore W3201880991C2777575956 @default.
• W3201880991 hasConceptScore W3201880991C2777652487 @default.
• W3201880991 hasConceptScore W3201880991C2778690821 @default.
• W3201880991 hasConceptScore W3201880991C2779244835 @default.
• W3201880991 hasConceptScore W3201880991C71924100 @default.
• W3201880991 hasConceptScore W3201880991C98274493 @default.
• W3201880991 hasFunder F4320321001 @default.

• next